A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents With Hereditary Angioedema
Phase of Trial: Phase III
Latest Information Update: 29 Mar 2019
Price : $35 *
At a glance
- Drugs Icatibant (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Sponsors Shire
- 29 Mar 2019 Last checked against ClinicalTrials.gov record.
- 29 Mar 2019 Argentina, Canada were planned locations as per European Clinical Trials Database record.
- 21 Mar 2018 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History